Intracerebroventricular Responses to Neuropeptide Y in the Antagonists
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Amylase Release from Rat Parotid Gland Slices C.L
Br. J. P!harmnic. (1981) 73, 517-523 THE EFFECTS OF SUBSTANCE P AND RELATED PEPTIDES ON a- AMYLASE RELEASE FROM RAT PAROTID GLAND SLICES C.L. BROWN & M.R. HANLEY MRC Neurochemical Pharmacology Unit, Medical Research Council Centre, Medical School, Hills Road, Cambridge CB2 2QH 1 The effects of substance P and related peptides on amylase release from rat parotid gland slices have been investigated. 2 Supramaximal concentrations (1 F.M) of substance P caused enhancement of amylase release over the basal level within 1 min; this lasted for at least 40 min at 30°C. 3 Substance P-stimulated amylase release was partially dependent on extracellular calcium and could be inhibited by 50% upon removal of extracellular calcium. 4 Substance P stimulated amylase release in a dose-dependent manner with an ED50 of 18 nm. 5 All C-terminal fragments of substance P were less potent than substance P in stimulating amylase release. The C-terminal hexapeptide of substance P was the minimum structure for potent activity in this system, having 1/3 to 1/8 the potency of substance P. There was a dramatic drop in potency for the C-terminal pentapeptide of substance P or substance P free acid. Physalaemin was more potent than substance P (ED50 = 7 nM), eledoisin was about equipotent with substance P (ED5o = 17 nM), and kassinin less potent than substance P (ED50 = 150 nM). 6 The structure-activity profile observed is very similar to that for stimulation of salivation in vivo, indicating that the same receptors are involved in mediating these responses. -
Back Matter (PDF)
MOLECULAR PHARMACOLOGY 26:605-609 AUTHOR INDEX FOR VOLUME 26 A berg, Aaron, Watanabe, Kyoichi A., Fox, Jack J., and Philips, Frederick S. Metabolic Competition Studies of 2’-Fluoro-S-iodo-l- Albengres, Edith. See Urien, Riant, Brioude, and Tillement, 322 f3-D-arabinofuranosylcytosine in Vero Cells and Herpes Simplex Albuquerque, E. X. See Aracava, Ikeda, Daly, and Brooks, 304 Type 1-Infected Vero Cells, 587 See Ikeda, Aronstam, Daly, and Aracava, 293 Christie, Nelwyn T. See Cantoni, Swann, Drath, and Costa, 360 Ambler, S. Kelly, Brown, R. Dale, and Taylor, Palmer. The Chrivia, John. See Bolger, Dionne, Johnson, and Taylor, 57 Relationship between Phosphatidylinositol Metabolism and Mobili- Colacino, Joseph M. See Chou, Lopez, Feinberg, Watanabe, Fox, and zation of Intracellular Calcium Elicited by Alpha,-Adrenergic Recep- Philips, 587 tar Stimulation in BC3H-1 Muscle Cells, 405 Collins, Sheila, and Marletta, Michael A. Carcinogen-Binding Aracava, Y. Ikeda, S. R., Daly, J. W., Brookes, N., and Albu- Proteins: High-Affinity Binding Sites for Benzo[ajpyrene in Mouse querque, E. X. Interactions of Bupivacaine with Ionic Channels of Liver Distinct from the Ah Receptor, 353 the Nicotonic Receptor: Analysis of Single-Channel Currents, 304 Cooper, Dermot M. F. See Sadler and Mailer, 526 See Ikeda, Aronstam, Daly, and Albuquerque, 293 Corbett, Michael D. See Doerge, 348 Aronstam, R. S. See Ikeda, S. R. , Daly, J. W., Aracava, Y. , and Cormier, Ethel. See Jordan, Lieberman, Koch, Bagley, and Ruenitz, Albuquerque, E. X. , 293 272 Aub, Debra L. See Putney, McKinney, and Leslie, 261 Costa, Erminio. See Quach, Tang, Kageyama, Mocchetti, Guidotti, Meek, and Schwartz, 255 B Costa, Max. -
The Vanilloid Receptor and Hypertension1
Acta Pharmacologica Sinica 2005 Mar; 26 (3): 286–294 Invited review The vanilloid receptor and hypertension1 Donna H WANG2 Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI 48825, USA Key words Abstract TRP family; afferent neurons; capsaicin; Mammalian transient receptor potential (TRP) channels consist of six related pro- calcitonin gene-related peptide; substance P; tein sub-families that are involved in a variety of pathophysiological function, and vanilloid receptor; renin-angiotensin- aldosterone system; endothelin, sympathetic disease development. The TRPV1 channel, a member of the TRPV sub-family, is nervous system; salt-sensitive hypertension identified by expression cloning using the “hot” pepper-derived vanilloid com- pound capsaicin as a ligand. Therefore, TRPV1 is also referred as the vanilloid 1 This work was supported in part by National receptor (VR1) or the capsaicin receptor. VR1 is mainly expressed in a subpopula- Institutes of Health (grants HL-52279 and tion of primary afferent neurons that project to cardiovascular and renal tissues. HL-57853) and a grant from the Michigan These capsaicin-sensitive primary afferent neurons are not only involved in the Economic Development Corporation. 2 Correspondence to Donna H WANG, MD. perception of somatic and visceral pain, but also have a “sensory-effector” function. Phn 1-517-432-0797. Regarding the latter, these neurons release stored neuropeptides through a cal- Fax 1-517-432-1326. cium-dependent mechanism via the binding of capsaicin to VR1. The most studied E-mail [email protected] sensory neuropeptides are calcitonin gene-related peptide (CGRP) and substance Received 2004-08-10 P (SP), which are potent vasodilators and natriuretic/diuretic factors. -
And Substance P and Dumping SEIKI ITO, YOICHI IWASAKI, TAKESHI
Tohoku J. exp. Med., 1981, 135, 11-21 Neurotensin and Substance P and Dumping Syndrome SEIKI ITO, YOICHI IWASAKI,TAKESHI MOMOTSU, KATSUMI TAKAI,AKIRA SHIBATA, YOICHI MATSUBARA* and TERUKAZU MUTO* The First Department of Internal Medicine and * the First Department of Surgery, Niigata University School of Medicine, Niigata 95.E ITO, S., IWASAKI, Y., MOMOTSU, T., TAKAI, K., SHIBATA, A., MATSUBARA, Y, and MUTO, T. Neurotensin and Substance P and Dumping Syndrome. Tohoku J. exp. Med., 1981, 135 (1), 11-21 To investigste the pathophysiologi- cal relation between releases of gut hormones and dumping syndrome, plasma radioimmunoassayable neurotesin, substance P, glucagon-like immunoreactivity (GLI), insulin and blood sugar were measured in both gastrectomized patients and control subjects after 50 g oral glucose tolerance tests. Remarkable rises of radioimmunoassayable neurotesin and GLI were found in all gastrectomized patients, but not in control subjects. In contrast, plasma radioimmunoassayable substance P responses were not detected in either gastrectomized patients or control subjects. There were three patients with symptoms of dumping syndrome in the early stage of the test. Plasma radioimmunoassayable neurotensin responses in two out of these three were higher than those in other patients, though the other patient with symptoms had the same degree of neurotensin elevation as patients with no symptoms. In view of the pharmacological effects of neurotensin, it could not be ruled out that a part of the early symptoms of dumping syndrome -
Effect of Bradykinin and Eledoisin on Renal Function in the Dog Department of Internal Medicine (Prof. T. Torikai), Tohoku Unive
Tohoku J. exp. Med., 1966, 89, 69-76 Effect of Bradykinin and Eledoisin on Renal Function in the Dog Takashi Furuyama,. Chikara Suzuki, Hiroshi Saito, Yozo Onozawa , Ryuji Shioji, Shozo Rikimaru, Keishi Abe and Kaoru Yoshinaga Department of Internal Medicine (Prof. T. Torikai), Tohoku University School of Medicine, Sendai Bradykinin (0.05, 0.1 and 0.2 ƒÊg/kg/min) and eledoisin (0.5, 1.0, 5.0 and 10.0ng/kg/min) were infused directly into the left renal artery of anesthetized dogs to demonstrate the effects of these peptides on renal function. Urinary volume, endogenous creatinine clearance (GFR), PAR clearance (RPF) and excretion of electrolytes were increased by infusion of these two peptides, but no constant change was observed in UK/U ,Va ratio. These data demonstrate that the increase in urinary output and electrolyte excretion is caused by the augmentation of tubular load of solutes which resulted from the increase of RPF and GFR. Tachy phylaxis was observed in dogs which received repeated infusions of bradykinin but this phenomenon was less distinct in the case of eledoisin. Bradykinin is a nonapeptide formed by the action of kinin-forming enzymes upon alpha-2-globulin fraction of the plasma and it plays an important role in the local control of blood flow to certain tissues. On the other hand, eledoisin isolated from the salivary gland of Eledone, is endecapeptide having powerful kinin-like activity2. Bradykinin and eledoisin administered intravenously produce reduction in systemic blood pressure because of vasodilator action of the peptides.2,3 Since the change in systemic blood pressure affects renal function in experiments with intravenous infusion of the peptides, it is difficult to reveal their direct action on the kidney. -
Biologically Active Peptides from Australian Amphibians
Biologically Active Peptides from Australian Amphibians _________________________________ A thesis submitted for the Degree of Doctor of Philosophy by Rebecca Jo Jackway B. Sc. (Biomed.) (Hons.) from the Department of Chemistry, The University of Adelaide August, 2008 Chapter 6 Amphibian Neuropeptides 6.1 Introduction 6.1.1 Amphibian Neuropeptides The identification and characterisation of neuropeptides in amphibians has provided invaluable understanding of not only amphibian ecology and physiology but also of mammalian physiology. In the 1960’s Erspamer demonstrated that a variety of the peptides isolated from amphibian skin secretions were homologous to mammalian neurotransmitters and hormones (reviewed in [10]). Erspamer postulated that every amphibian neuropeptide would have a mammalian counterpart and as a result several were subsequently identified. For example, the discovery of amphibian bombesins lead to their identification in the GI tract and brain of mammals [394]. Neuropeptides form an integral part of an animal’s defence and can assist in regulation of dermal physiology. Neuropeptides can be defined as peptidergic neurotransmitters that are produced by neurons, and can influence the immune response [395], display activities in the CNS and have various other endocrine functions [10]. Generally, neuropeptides exert their biological effects through interactions with G protein-coupled receptors distributed throughout the CNS and periphery and can affect varied activities depending on tissue type. As a result, these peptides have biological significance with possible application to medical sciences. Neuropeptides isolated from amphibians will be discussed in this chapter, with emphasis on the investigation into the biological activity of peptides isolated from several Litoria and Crinia species. Many neurotransmitters and hormones active in the CNS are ubiquitous among all vertebrates, however, active neuropeptides from amphibian skin have limited distributions and are unique to a restricted number of species. -
Wo 2009/015286 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 29 January 2009 (29.01.2009) WO 2009/015286 A2 (51) International Patent Classification: Not classified AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (21) International Application Number: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, PCT/US2008/071055 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (22) International Filing Date: 24 July 2008 (24.07.2008) MX, MY,MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 60/961,872 24 July 2007 (24.07.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): NEXBIO, European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, INC. [US/US]; 10665 Sorrento Valley Road, San Diego, California 92121 (US). FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, (72) Inventors; and CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). -
The Hydrolysis of Inositol Phospholipid in Mouse Exocrine Pancreas
THE HYDROLYSIS OF INOSITOL PHOSPHOLIPID IN IVIOUSE EXOCRINE PANCREAS ,,r'ir:::'r]. *. DEGREE OF DOCTOR OF PHILOSOPHY of The Department of Physiology Uni vers i ty of Adel ai de , South Austra'l i a by KARIN ANNE TENNES B.Sc.(Hons.) 1984 fi.6sx'-eL,'( I ? - S" 8:'" TABLE OF CONTENTS Page SUMMARY . (v.ii) DECLARATI0N (x) AC KNOI,ILEDGEMENTS (xi ) LIST OF TABLES (xii) LIST 0F FIGURES (xiv) CHAPTER 1 : INTRODUCTION 2 CHAPTER 2 LITERATURE REVIEI^, I 2.t PANCRIATIC STRUCTURE AND FUNCTION 9 2.2 INTERACTION BETI^IEEN ENDOCRINE AND EXOCRINE PANCREAS 23 2.3 PANCREATIC SECRETAGOGUES 27 2.3 (a) Secretagogues which Increase the Intra- cel I ul ar Concentrati on of Cal ci um 27 2.3 (b) Secretagogues wh'ich Cause an Increase in the Intracel I ul ar Concentrati on of cAl'lP 28 2.3 (c) Pancreatic Secretagogues which do not Appear to Act via Increas'ing the Intra- cellular Concentration of Calcium or cAMP 42 2.4 THE ROLE OF CALCIUM IN PANCREATIC ENZYIrIE SECRETION 47 2.a G) Evidence for the Involvement of Calcium in Pancreatic Enzyme Secretion 47 2.4 (b) Evidence for the Involvement of Changes i n l,lembrane Potenti al i n Protei n Secreti on 49 2.a (c) Cytop'lasmic Calcium Concentrations in Pancreatic Acinar Cells 56 ( j ) (i i ) Page 2.5 CALCIUM FLUXES IN PANCREATIC ACINAR CELLS : THE EVENTS LEADING TO INCREASID INTRACELLULAR CALCIUM CON CENTRATI ON 60 2.6 THE RELATIONSHIP BETI^IEEN INHIBITION OF PROTEIN SECRETION, CYTOSOLIC CALCIUM CONCENTRATION AND RECEPTOR OCCUPATION IN THE EXOCRINE PANCREAS 70 2.7 CALCIUM-ACTIVATED STIMULUS-SECRETION COUPLING IN EXOCRINE -
JOHN R. VANE Wellcome Research Laboratories, Langley Court, Beckenham, Kent, U.K
ADVENTURES AND EXCURSIONS IN BIO- ASSAY: THE STEPPING STONES TO PROSTACYCLIN Nobel lecture, 8 December, 1982 by JOHN R. VANE Wellcome Research Laboratories, Langley Court, Beckenham, Kent, U.K. Physiology has spawned many biological sciences, amongst them my own field of pharmacology. No man has made a more important contribution to the fields of physiology and pharmacology than Sir Henry Dale (1875-1968, Nobel Laureate in Physiology or Medicine in 1936). Dale had a great influence not only on British pharmacology in general but also on my own scientific endea- vours. Indeed, I can put forward a strong case for considering myself as one of Dale’s scientific grandchildren. My early days as a pharmacologist were in- fluenced not only by Dale himself but also by his school of colleagues, including Burn, Gaddum and von Euler. It was Burn who taught me the principles and practice of bioassay. Some of Gaddum’s first publications were on the develop- ment of specific and sensitive methods for biological assay and he maintained a deep interest in this subject for the rest of his life (1). In 1964 he said “the pharmacologist has been a ‘jack of all trades’ borrowing from physiology, biochemistry, pathology, microbiology and statistics – but he has developed one technique of his own, and that is the technique of bioassay” (2). Expensive, powerful and sophisticated chemical methods, such as gas chro- matography and mass spectrometry, have been developed and perfected for detection and quantification of prostaglandins (PGs) and related substances. One should not forget, however, that starting with the discovery and isolation of prostaglandins by von Euler (3; see also Bergstrom in this volume), biologi- cal techniques and bioassay have contributed very substantially to the develop- ment of the field. -
(12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
US 2015.0050713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov et al. (43) Pub. Date: Feb. 19, 2015 (54) TECHNOLOGY FOR THE PREPARATION OF Publication Classification MCROPARTICLES (51) Int. Cl. (71) Applicant: Ansun Biopharma, Inc., San Diego, CA CI2N 9/96 (2006.01) (US) CI2N 7/00 (2006.01) CI2N IS/II3 (2006.01) (72) Inventors: Michael P. Malakhov, San Francisco, C07D 305/.4 (2006.01) CA (US); Fang Fang, Rancho Santa Fe, C07K 4/765 (2006.01) CA (US) C07K9/00 (2006.01) (52) U.S. Cl. CPC ................ CI2N 9/96 (2013.01); C07K 14/765 (21) Appl. No.: 14/341,502 (2013.01); C07K9/008 (2013.01): CI2N 15/113 (2013.01); C07D 305/14 (2013.01); (22) Filed: Jul. 25, 2014 CI2N 7/00 (2013.01); C12N 2770/00051 (2013.01) O O USPC ........... 435/188: 530/363; 530/350, 530/367; Related U.S. Application Data 530/385:536/16.8; 536/13.7: 540/336; 530/317; (63) Continuation of application No. 13/874,424, filed on 536/24.5; 530/328; 552/203; 549/510; 435/238 Apr. 30, 2013, now abandoned, which is a continuation (57) ABSTRACT of application No. 13/250,653, filed on Sep. 30, 2011, Mi h duced b tacti lution of a now abandoned, which is a continuation of application 1crospneres are produced by contacting a sol No. 12/179.520, filed on Jul 24, 2008, now aban- macromolecule or small molecule in a solvent with an ant1 doned sa- 1 ws s s Solvent and a counterion, and chilling the solution. -
Neuropeptides in the Human Brainstem
Investigación Clínica ISSN: 0535-5133 Universidad del Zulia Duque-Díaz, Ewing; Martínez-Rangel, Diana; Ruiz-Roa, Silvia Neuropeptides in the human brainstem Investigación Clínica, vol. 59, no. 2, 2018, April-June, pp. 161-178 Universidad del Zulia DOI: https://doi.org/10.22209/IC.v59n2a06 Available in: https://www.redalyc.org/articulo.oa?id=372960175007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative Invest Clin 59(2): 161 - 178, 2018 https//doi.org/10.22209/IC.v59n2a06 Neuropeptides in the human brainstem. Ewing Duque-Díaz1, Diana Martínez-Rangel1 and Silvia Ruiz-Roa1,2. 1Universidad de Santander UDES. Laboratory of Neuroscience, School of Medicine, Bucaramanga, Colombia. 2Universidad de Santander UDES. Laboratory of Neuroscience, Nursing Program, Bucaramanga, Colombia. Key words: neuropeptides; mesencephalon; pons; medulla oblongata; human. Abstract. The physiological importance of the brainstem has made it one of the most studied structures of the central nervous system of mammals (in- cluding human). This structure receives somatic and visceral inputs and its neurons send motor efferences by means of the cranial nerves, which innervate the head, neck and sensory organs, and it mediates in several actions such as movement, pain, cardiovascular, respiratory, salivary, sleep, vigil and sexual mechanisms. Most of these actions are mediated by neuroactive substances denominated neuropeptides, which are short amino acid chains widespread dis- tributed in the nervous system, that play a role in neurotransmission, neuro- modulation (paracrine and autocrine actions), and act as neurohormones. -
Prediction of Peptide Retention Times in High-Pressure Liquid Chromatography on the Basis of Amino Acid Composition (Lipophilicity/Separation Techniques) JAMES L
Proc. Natl. Acad. Sci. USA Vol. 77, No. 3, pp. 1632-1636, March 1980 Medical Sciences Prediction of peptide retention times in high-pressure liquid chromatography on the basis of amino acid composition (lipophilicity/separation techniques) JAMES L. MEEK Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032 Communicated by Bruce Merrifield, December 17,1979 ABSTRACT Analysis of peptides by reverse-phase high- on octadecylsilyl silica gel is a quite different process from oc- pressure liquid chromatography would be simplified if retention tanol/water partition and from the unavailability of hydro- times could be predicted by summing the contribution to re- groups of the peptides. It is the tention of each of the peptide's amino acid side chains. This phobicity data for terminal paper describes the derivation of values ("retention coeffi- purpose of this paper to show that "retention coefficients" can cients") that represent the contribution to retention of each of be derived directly from HPLC data for all amino acids and the common amino acids and end groups. Peptide retention end groups such that the retention time of a peptide can be times were determined on a Bio-Rad "ODS" column at room predicted from the sum of the retention coefficients for each temperature with a linear gradient from 0.1 M NaCIO4, pH 7.4 amino acid and end group. or 2.1, at 0 min to 60% acetonitrile/0.1 M NaCIO4 at 80 min. The NaClO4, a chaotropic agent, was added to improve peak shape and to minimize conformational effects.